Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=195 Early ART to Limit Infection and Establishment of Reservoir
HIV-1 Infection
Primary: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) — 0.00; 0.00; 0.00; 0.10 Proportion of participants — p=0.48
Phase 2 N=14 A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
HIV Infections
Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
Phase 1 N=16 Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
HIV-1
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 3 N=32 Effects of Intensive cART During Acute/Early HIV Infection
Acute HIV Infection
Primary: Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo…
Phase 2 N=15 Enhancement by Poly-ICLC During HIV-1 Infection
HIV-1 Infected Adults With Chronic HIV-1 Infection
Primary: Number Participants With Adverse Events — 11; 3 Participants
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
N/A N=219 HIV-Tb Confections Among HIV Patients
HIV
Primary: Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center. — 48 participants
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
N/A N=42 New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
HIV Infections
Primary: Combined Endpoint Including HIV RNA and HIV DNA — 0; 0 Participants
N/A N=114 Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
N/A N=30 HIV-related Insomnia and Inflammation
Hiv · Insomnia
Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
N/A N=18 Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Acute HIV Infection
Primary: Mean White Blood Cell Count Between Treatment Groups at 2 Months — 5904; 4918 white blood cells per microliter (mcL).
Phase 3 N=33 Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
HIV
Primary: Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 — 28 participants
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
Phase 2 N=7 Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants
N/A N=300 HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting
Hiv · HIV Infections · AIDS
Primary: Prevalence of HIV Infection — 6 Participants
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
N/A N=16 The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection
HIV Infection
Primary: Mean Change From Baseline Plasma HIV RNA (Log Copies/mL) — 5.4 log copies/mL plasma
Phase 1 N=16 GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Part 1:Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 3; 2; 4; 3 Participants
Phase 1 N=10 VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption
HIV
Primary: Number of Grade 3 or Higher Adverse Events — 0 Events
Phase 2 N=24 Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
HIV Infections
Primary: HIV Viral Load — -0.18; -0.05; 0.002; 0.26 HIV RNA copies/mL — p=0.008
Phase 4 N=92 Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Acute HIV Infection · HIV Infections
Primary: Number of Participants Without Virologic Failure at Week 24 — 81 Participants
Phase 1 N=21 Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients
HIV-infection
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
Phase 2 N=22 VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
HIV Infections
Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…